Intensive Blood Pressure Targets Below 130/80 mmHg Benefit Patients Across the Cardiovascular-Kidney-Metabolic Syndrome Spectrum
Posted inCardiology Nephrology news

Intensive Blood Pressure Targets Below 130/80 mmHg Benefit Patients Across the Cardiovascular-Kidney-Metabolic Syndrome Spectrum

A post hoc analysis of the CRHCP trial demonstrates that intensive blood pressure control (<130/80 mmHg) significantly reduces major adverse **Confirming JSON Structure** I'm now fully focused on creating the JSON object. I've re-reviewed both schemas, and am following the most up-to-date and complete instructions. I'm double-checking the required fields, especially `thumbnail`, `lang`, and `multilang`, to ensure the final output is perfectly structured and valid. cardiovascular events across CKM syndrome stages 2 through 4, providing a favorable net clinical benefit despite an increased risk of hypotension.
Intensive Blood Pressure Control to <120 mmHg: Holistic Benefits Across Frailty, Quality of Life, and Microvascular Health in the ESPRIT Trial
Posted inCardiology Internal Medicine news

Intensive Blood Pressure Control to <120 mmHg: Holistic Benefits Across Frailty, Quality of Life, and Microvascular Health in the ESPRIT Trial

The ESPRIT trial reveals that targeting systolic blood pressure below 120 mmHg significantly reduces cardiovascular events across diverse populations, including frail patients and those with diabetes, while uniquely improving retinal microvascular health and maintaining patient quality of life.
Precision Hypertension Management: Haptoglobin Phenotype Predicts Cardiovascular Benefit from Intensive Blood Pressure Control in Type 2 Diabetes
Posted inCardiology Diabetes & Endocrinology news

Precision Hypertension Management: Haptoglobin Phenotype Predicts Cardiovascular Benefit from Intensive Blood Pressure Control in Type 2 Diabetes

A post-hoc analysis of the ACCORD trial reveals that intensive blood pressure control significantly reduces cardiovascular and stroke risk in haptoglobin 1 allele carriers, but not in those with the Hp2-2 phenotype, suggesting a genotype-driven approach to hypertension management in diabetes.
Lowering Blood Pressure in Isolated Diastolic Hypertension: Evidence Supports Risk Reduction Across All Diastolic Levels
Posted inCardiology Internal Medicine news

Lowering Blood Pressure in Isolated Diastolic Hypertension: Evidence Supports Risk Reduction Across All Diastolic Levels

A large-scale meta-analysis reveals that lowering blood pressure in patients with isolated diastolic hypertension (IDH) provides cardiovascular protection comparable to those with systolic elevations, suggesting that diastolic thresholds alone should not preclude treatment in high-risk individuals.
Beyond Standard Risk Factors: High-Sensitivity C-Reactive Protein as a Critical Driver of Cardiovascular Risk Prediction
Posted inCardiology Internal Medicine news

Beyond Standard Risk Factors: High-Sensitivity C-Reactive Protein as a Critical Driver of Cardiovascular Risk Prediction

Recent large-scale studies demonstrate that high-sensitivity C-reactive protein (hsCRP) is a potent, stable predictor of cardiovascular events, even in individuals without traditional risk factors. Despite its clinical utility in improving risk reclassification, barriers to widespread adoption in clinical practice remain.